Anti-HBc-nonreactive occult hepatitis B infections with HBV genotypes B and C in vaccinated immunocompetent adults.


Journal

Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672

Informations de publication

Date de publication:
11 2022
Historique:
received: 07 03 2022
accepted: 01 07 2022
pubmed: 26 7 2022
medline: 12 10 2022
entrez: 25 7 2022
Statut: ppublish

Résumé

Absence of anti-HBc reactivity with detectable anti-HBs was observed in blood donors with occult hepatitis B virus (HBV) infection (OBI). The prevalence and mechanisms underlying this uncommon condition were investigated over time in Chinese blood donors with OBI. Isolated anti-HBs OBI status was identified from 466,911 donors from Dalian, China, and monitored in follow-up (range: 2.6-84.3 months). HBV vaccination status was documented, and infecting viral strains were characterized. Of 451 confirmed OBIs (1:1035), 43 (9.5%; 1:10,858) had isolated anti-HBs as only serological marker. Isolated anti-HBs OBIs differed from anti-HBc-reactive OBIs by significantly younger age (median 24 years), higher HBV DNA (median: 20 IU/ml) and anti-HBs (median 60.5 IU/L) levels, paucity of mutations in HBV Core and S proteins, and high vaccination rate (72%). Vaccinated isolated anti-HBs OBIs (n = 31) differed from unvaccinated (n = 11) by significantly younger age (22 vs 38 years), higher anti-HBs level at index (48% vs 9% with anti-HBs >100 IU/L) and higher frequency of anti-HBs immune response (44% vs 20%). Of 15 vaccinated and 5 unvaccinated OBIs follow-up, 65% (8 vaccinated and 5 unvaccinated) became HBV DNA negative suggesting aborted recent infection, while 35% (7 vaccinated) had low persistent viraemia 2 to 65 months post index. In conclusion, isolated anti-HBs OBI in Chinese blood donors appears associated with young, vaccinated, adults exposed to HBV who predominantly develop low level aborted infection revealed by transient HBV DNA and immune anti-HBs response. However, a subset of individuals still experienced low but persistent viral replication whose clinical outcome remains uncertain.

Identifiants

pubmed: 35876456
doi: 10.1111/jvh.13733
pmc: PMC9804389
doi:

Substances chimiques

DNA, Viral 0
Hepatitis B Antibodies 0
Hepatitis B Core Antigens 0
Hepatitis B Surface Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

958-967

Informations de copyright

© 2022 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.

Références

J Clin Virol. 2017 Aug;93:46-52
pubmed: 28622640
Emerg Microbes Infect. 2019;8(1):1337-1346
pubmed: 31516090
J Viral Hepat. 2017 Aug;24(8):645-653
pubmed: 28182307
Transfusion. 2009 Jun;49(6):1126-35
pubmed: 19392770
J Med Virol. 2017 Dec;89(12):2130-2137
pubmed: 28543299
PLoS One. 2016 Nov 11;11(11):e0166317
pubmed: 27835694
J Infect Dis. 2014 Mar;209(6):845-54
pubmed: 24158960
Clin Vaccine Immunol. 2013 Feb;20(2):269-75
pubmed: 23254298
J Viral Hepat. 2022 Nov;29(11):958-967
pubmed: 35876456
J Med Virol. 1999 Aug;58(4):325-31
pubmed: 10421397
J Hepatol. 1993 Feb;17(2):150-4
pubmed: 8445229
Hepatology. 1992 Jul;16(1):24-30
pubmed: 1535607
N Engl J Med. 2011 Jan 20;364(3):236-47
pubmed: 21247314
Blood Transfus. 2014 Apr;12(2):172-9
pubmed: 24333061
Gut. 2019 Feb;68(2):313-321
pubmed: 29959168
J Hepatol. 2008 Oct;49(4):537-47
pubmed: 18602718
Ann Intern Med. 2005 Mar 1;142(5):333-41
pubmed: 15738452
Front Microbiol. 2020 Dec 14;11:616023
pubmed: 33381105
J Hepatol. 1996 Feb;24(2):155-60
pubmed: 8907568
Medicine (Baltimore). 2016 Dec;95(49):e5625
pubmed: 27930595
Int J Infect Dis. 2020 Mar;92:38-45
pubmed: 31877352
Intervirology. 2001;44(4):243-9
pubmed: 11509887
PLoS One. 2013 Aug 12;8(8):e70768
pubmed: 23951004
Hepatol Int. 2020 Jul;14(4):503-512
pubmed: 32472310
J Hepatol. 2019 Aug;71(2):397-408
pubmed: 31004683
Transfusion. 2017 Jan;57(1):24-35
pubmed: 27673757
Gut. 2012 Dec;61(12):1744-53
pubmed: 22267593
Front Microbiol. 2021 Aug 06;12:695384
pubmed: 34421849
Liver Int. 2020 Jan;40(1):92-100
pubmed: 31518482
Blood Transfus. 2022 Jan;20(1):8-17
pubmed: 33370226
J Viral Hepat. 2017 Sep;24(9):797-803
pubmed: 28342241
Transfusion. 2020 Feb;60(2):334-342
pubmed: 31909495
Liver Int. 2019 Jun;39(6):1052-1061
pubmed: 30790411
J Clin Virol. 2009 Oct;46(2):124-8
pubmed: 19631583

Auteurs

Xuelian Deng (X)

Dalian Blood Center, Dalian, China.

Xiaohan Guo (X)

Dalian Blood Center, Dalian, China.

Hongfang Gu (H)

Dalian Public Health Clinical Center, Dalian, China.

Dong Wang (D)

Dalian Blood Center, Dalian, China.

Syria Laperche (S)

Department of Blood Transmitted Agents, National Institute of Blood Transfusion, Paris, France.

Jean-Pierre Allain (JP)

University of Cambridge, Cambridge, UK.

Liang Zang (L)

Dalian Blood Center, Dalian, China.

Daniel Candotti (D)

Department of Blood Transmitted Agents, National Institute of Blood Transfusion, Paris, France.
Department of Virology, Henri Mondor Hospital, AP-HP, Créteil, France.
University of Paris-Est, INSERM U955, IMRB, Créteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH